Disease activity after natalizumab discontinuation in multiple sclerosis: reactivation or rebound?

被引：0
|
作者：
Borriello, G. [1 ]
Prosperini, L. [1 ]
Mancinelli, C. [1 ]
Fubelli, F. [1 ]
Gianni, C. [1 ]
Marinelli, F. [1 ]
Pozzilli, C. [1 ]
机构：
[1] S Andrea Hosp, Rome, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P529
引用
收藏
页码：S228 / S228
页数：1
相关论文
共 50 条
  • [31] Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation (vol 38, 101498, 2020)
    Mustonen, Tiina
    Rauma, Ikka
    Hartikainen, Paivi
    Kruger, Johanna
    Niiranen, Marja
    Selander, Tuomas
    Simula, Sakari
    Remes, Anne M.
    Kussisto, Hanna
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
  • [32] Cyclophosphamide pulses therapy after natalizumab discontinuation in Multiple Sclerosis patients
    Capobianco, M.
    Lo Re, M.
    Sangalli, F.
    Moiola, L.
    Comi, G.
    Perini, P.
    Gallo, P.
    Danni, M.
    Provinciali, L.
    Repice, A.
    Massacesi, L.
    Patti, F.
    Messina, S.
    Laroni, A.
    Mancardi, G. L.
    Calabrese, M.
    Monaco, S.
    Pucci, E.
    Giuliani, G.
    Bertolotto, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 475 - 475
  • [33] Predicting Natalizumab Discontinuation due to Breakthrough Disease in Multiple Sclerosis Patients
    Conway, Devon
    Harris, Haleigh
    Hersh, Carrie
    Hua, Le
    NEUROLOGY, 2019, 92 (15)
  • [34] Reactivation of Human Herpesvirus after Natalizumab Treatment in Patients with Multiple Sclerosis
    Yao, Karen
    Hoest, Christel
    Stuve, Olaf
    Jacobson, Steven
    JOURNAL OF NEUROVIROLOGY, 2009, 15 : 107 - 107
  • [35] Reducing Rebound Disease Activity in Relapsing Multiple Sclerosis Patients Electively Transitioned from Natalizumab to Teriflunomide
    Cohan, Stanley
    Edwards, Keith
    Gervasi, Tiffany
    Chen, Chiayi
    O'Connor, Judy
    Smoot, Kyle
    Kresa-Reahl, Kiren
    NEUROLOGY, 2017, 88
  • [36] Fatal rebound of multiple sclerosis after fingolimod discontinuation: a neuropathological description
    Vercellino, M.
    Cavalla, P.
    Capello, E.
    Bandini, F.
    Uccelli, A.
    Giordana, M. T.
    Mancardi, G. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 794 - 794
  • [37] Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy
    Sorensen, P. S.
    Oturai, A.
    Sellebjerg, F.
    Magyari, M.
    Koch-Henriksen, N.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 491 - 491
  • [38] Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
    Gonzalez-Suarez, Ines
    Rodriguez de Antonio, Luis
    Orviz, Aida
    Moreno-Garcia, Sara
    Valle-Arcos, Maria D.
    Matias-Guiu, Jordi A.
    Valencia, Cristina
    Jorquera Moya, Manuela
    Oreja-Guevara, Celia
    BRAIN AND BEHAVIOR, 2017, 7 (04):
  • [39] Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation
    Martinelli, Vittorio
    Dalla Costa, Gloria
    Sangalli, Francesca
    Colombo, Bruno
    Robotti, Micaela
    Moiola, Lucia
    Comi, Giancarlo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 57 - 59
  • [40] Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
    Havla, Joachim
    Tackenberg, Bjoern
    Hellwig, Kerstin
    Meinl, Ingrid
    Krumbholz, Markus
    Seitz, Florian
    Eienbroeker, Christian
    Gold, Ralf
    Hohlfeld, Reinhard
    Kleiter, Ingo
    Kuempfel, Tania
    JOURNAL OF NEUROLOGY, 2013, 260 (05) : 1382 - 1387
12345